REDWOOD CITY, Calif., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology
company dedicated to delivering innovative, biometric remote monitoring solutions, is pleased to announce that it has filed its
response to the FDA with the additional information requested. The company expects to receive further communication from the FDA
within 30 days.
A 510(k) is a premarket submission made to the FDA to demonstrate that the device to be marketed is as safe and effective, at
the very least, as a legally marketed device. It is an interactive process with reviewers who use manufacturer evidence to assess
the substantial equivalence of the new device. The reviewers rely on FDA guidance documents and recognized safety standards to
determine the equivalence of this device to devices that have previously been commercialized.
Biotricity is pleased that it was able to collect all the information requested and submit its response in a timely manner. The
company is confident in its FDA process and believes it is well positioned to achieve its target timetable.
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring
solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and
lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting
health management into the hands of the individual. The company aims to support the self-management of critical and chronic
conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
To learn more, visit www.biotricity.com or follow on
Twitter: @biotricity_inc Facebook: facebook.com/biotricity/ or
LinkedIn: linkedin.com/company/biotricity-measuring-vitals
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are
generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,”
“estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or
comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and
objectives of management for future operations, including plans or objectives relating to the design, development and
commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including
income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial
items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to
operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such
forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not
be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and
assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control
over. Actual results and the timing of certain events and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy
of the forward-looking statements or cause actual results to differ materially from expected or desired results may include,
without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated
with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to
expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product
diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and
the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described
in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in
order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com, 508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
